Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · October 09, 2015

Empagliflozin as an Adjunct to Insulin Therapy

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Impact of Empagliflozin Added on to Basal Insulin in Type 2 Diabetes Inadequately Controlled on Basal Insulin: A 78-Week Randomized, Double-Blind, Placebo-Controlled Trial
Diabetes Obes Metab 2015 Oct 01;17(10)936-948, J Rosenstock, A Jelaska, C Zeller, G Kim, UC Broedl, HJ Woerle

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading